155 related articles for article (PubMed ID: 36617466)
1. circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis.
Qin K; Zhang F; Wang H; Wang N; Qiu H; Jia X; Gong S; Zhang Z
BMB Rep; 2023 Mar; 56(2):184-189. PubMed ID: 36617466
[TBL] [Abstract][Full Text] [Related]
2. Erratum to: circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis.
Qin K; Zhang F; Wang H; Wang N; Qiu H; Jia X; Gong S; Zhang Z
BMB Rep; 2024 Feb; 57(2):122. PubMed ID: 38416113
[TBL] [Abstract][Full Text] [Related]
3. miR-219-5p attenuates cisplatin resistance of ovarian cancer by inactivating Wnt/β-catenin signaling and autophagy via targeting HMGA2.
Song Z; Liao C; Yao L; Xu X; Shen X; Tian S; Wang S; Xing F
Cancer Gene Ther; 2023 Apr; 30(4):596-607. PubMed ID: 36494581
[TBL] [Abstract][Full Text] [Related]
4. CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination.
Zhu Y; Liang L; Zhao Y; Li J; Zeng J; Yuan Y; Li N; Wu L
J Nanobiotechnology; 2024 Jan; 22(1):35. PubMed ID: 38243224
[TBL] [Abstract][Full Text] [Related]
5. Propofol decreases cisplatin resistance of non-small cell lung cancer by inducing GPX4-mediated ferroptosis through the miR-744-5p/miR-615-3p axis.
Han B; Liu Y; Zhang Q; Liang L
J Proteomics; 2023 Mar; 274():104777. PubMed ID: 36427803
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.
Dai J; Wei R; Zhang P; Kong B
J Transl Med; 2019 Jun; 17(1):190. PubMed ID: 31171023
[TBL] [Abstract][Full Text] [Related]
7. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
[TBL] [Abstract][Full Text] [Related]
8. Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner.
Gao Y; Huang Y
J Chemother; 2023 Apr; 35(2):117-130. PubMed ID: 35380509
[TBL] [Abstract][Full Text] [Related]
9. Erratum to: circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis.
Qin K; Zhang F; Wang H; Wang N; Qiu H; Jia X; Gong S; Zhang Z
BMB Rep; 2023 Jul; 56(7):416. PubMed ID: 37500559
[TBL] [Abstract][Full Text] [Related]
10. Circ_0026123 promotes cisplatin resistance and progression of ovarian cancer by upregulating RAB1A through sequestering miR-543.
Wei L; He W; Zhao H; Zhao P
Anticancer Drugs; 2022 Nov; 33(10):1069-1080. PubMed ID: 36255068
[TBL] [Abstract][Full Text] [Related]
11. MiR-30a-5p Enhances Cisplatin Sensitivity by Downregulating RIF1 in Ovarian Cancer.
Yao W; Wang Y; Huang M; Zhou J; Zheng R; Jin C; Zhang Y
Ann Clin Lab Sci; 2023 May; 53(3):418-426. PubMed ID: 37437929
[TBL] [Abstract][Full Text] [Related]
12. N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation.
Li H; Lin R; Zhang Y; Zhu Y; Huang S; Lan J; Lu N; Xie C; He S; Zhang W
Mol Cancer; 2024 Jan; 23(1):5. PubMed ID: 38184597
[TBL] [Abstract][Full Text] [Related]
13. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
14. Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1.
Zhuang L; Zhang B; Liu X; Lin L; Wang L; Hong Z; Chen J
Cell Biol Int; 2021 Oct; 45(10):2140-2149. PubMed ID: 34288231
[TBL] [Abstract][Full Text] [Related]
15. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
16. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
17. CircRNA circSTIL inhibits ferroptosis in colorectal cancer via miR-431/SLC7A11 axis.
Li Q; Li K; Guo Q; Yang T
Environ Toxicol; 2023 May; 38(5):981-989. PubMed ID: 36840697
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of circ-PIP5K1A overcomes resistance to cisplatin in ovarian cancer by miR-942-5p/NFIB axis.
Sheng H; Wang X
Anticancer Drugs; 2023 Feb; 34(2):214-226. PubMed ID: 36730637
[TBL] [Abstract][Full Text] [Related]
19. Circ_0067934 reduces JNK phosphorylation through a microRNA-545-3p/PPA1 axis to enhance tumorigenesis and cisplatin resistance in ovarian cancer.
Yin Y; Li J; Rong J; Zhang B; Wang X; Han H
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):261-274. PubMed ID: 35179434
[TBL] [Abstract][Full Text] [Related]
20. circRNA circARNT2 Suppressed the Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin by Targeting the miR-155-5p/PDK1 Axis.
Li Y; Zhang Y; Zhang S; Huang D; Li B; Liang G; Wu Y; Jiang Q; Li L; Lin C; Wei Z; Meng L
Mol Ther Nucleic Acids; 2021 Mar; 23():244-254. PubMed ID: 33425483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]